We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Read MoreHide Full Article
Thermo Fisher Scientific (TMO - Free Report) reported $10.69 billion in revenue for the quarter ended June 2023, representing a year-over-year decline of 2.6%. EPS of $5.15 for the same period compares to $5.51 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $10.99 billion, representing a surprise of -2.77%. The company delivered an EPS surprise of -5.16%, with the consensus EPS estimate being $5.43.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Thermo Fisher performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
Revenue Growth - Organic: -3% versus the five-analyst average estimate of -0.36%.
Revenues- Life Sciences Solutions: $2.46 billion versus the seven-analyst average estimate of $2.89 billion. The reported number represents a year-over-year change of -25.2%.
Revenues- Analytical Instruments: $1.75 billion versus $1.75 billion estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +8.8% change.
Revenues- Eliminations: -$465 million versus the seven-analyst average estimate of -$610.91 million.
Revenues- Laboratory Products and Biopharma Services: $5.83 billion versus $5.86 billion estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +5.3% change.
Revenues- Specialty Diagnostics: $1.11 billion versus the seven-analyst average estimate of $1.11 billion. The reported number represents a year-over-year change of +0.7%.
Operating Income- Life Sciences Solutions: $817 million versus the four-analyst average estimate of $1 billion.
Operating Income- Laboratory Products and Biopharma Services: $824 million versus the four-analyst average estimate of $814.76 million.
Operating Income- Specialty Diagnostics: $297 million compared to the $239.45 million average estimate based on four analysts.
Operating Income- Analytical Instruments: $432 million compared to the $421.22 million average estimate based on four analysts.
Shares of Thermo Fisher have returned +12% over the past month versus the Zacks S&P 500 composite's +5.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Thermo Fisher (TMO) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Thermo Fisher Scientific (TMO - Free Report) reported $10.69 billion in revenue for the quarter ended June 2023, representing a year-over-year decline of 2.6%. EPS of $5.15 for the same period compares to $5.51 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $10.99 billion, representing a surprise of -2.77%. The company delivered an EPS surprise of -5.16%, with the consensus EPS estimate being $5.43.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Thermo Fisher performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue Growth - Organic: -3% versus the five-analyst average estimate of -0.36%.
- Revenues- Life Sciences Solutions: $2.46 billion versus the seven-analyst average estimate of $2.89 billion. The reported number represents a year-over-year change of -25.2%.
- Revenues- Analytical Instruments: $1.75 billion versus $1.75 billion estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +8.8% change.
- Revenues- Eliminations: -$465 million versus the seven-analyst average estimate of -$610.91 million.
- Revenues- Laboratory Products and Biopharma Services: $5.83 billion versus $5.86 billion estimated by seven analysts on average. Compared to the year-ago quarter, this number represents a +5.3% change.
- Revenues- Specialty Diagnostics: $1.11 billion versus the seven-analyst average estimate of $1.11 billion. The reported number represents a year-over-year change of +0.7%.
- Operating Income- Life Sciences Solutions: $817 million versus the four-analyst average estimate of $1 billion.
- Operating Income- Laboratory Products and Biopharma Services: $824 million versus the four-analyst average estimate of $814.76 million.
- Operating Income- Specialty Diagnostics: $297 million compared to the $239.45 million average estimate based on four analysts.
- Operating Income- Analytical Instruments: $432 million compared to the $421.22 million average estimate based on four analysts.
View all Key Company Metrics for Thermo Fisher here>>>Shares of Thermo Fisher have returned +12% over the past month versus the Zacks S&P 500 composite's +5.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.